Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Merete B Long

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The European Respiratory Journal|May 22, 2025
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE studyKai Xian Thng, Pei Yee Tiew, Micheál Mac Aogáin, et al.
The Lancet. Respiratory Medicine|September 8, 2022
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trialHolly R Keir, Merete B Long, Hani Abo-Leyah, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
The Lancet. Respiratory Medicine|May 19, 2026
Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registriesRebecca C Hull, Yang Liu, Zu Cao, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The European Respiratory Journal|May 22, 2025
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE studyKai Xian Thng, Pei Yee Tiew, Micheál Mac Aogáin, et al.
The Lancet. Respiratory Medicine|September 8, 2022
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trialHolly R Keir, Merete B Long, Hani Abo-Leyah, et al.
The Lancet. Respiratory Medicine|April 27, 2026
Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort studyAmelia Shoemark, Emma D Johnson, Morven Shuttleworth, et al.
The Lancet. Respiratory Medicine|May 19, 2026
Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registriesRebecca C Hull, Yang Liu, Zu Cao, et al.
Pageof 4